Pharmaceuticals News and Research

RSS

Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Bayer HealthCare and the Drugs for Neglected Diseases initiative (DNDi) have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to treat river blindness (or onchocerciasis). The world's second leading infectious cause of blindness, river blindness is a neglected tropical disease caused by a filarial worm.

10 Dec 2014

Study: Simeprevir-based therapy proves effective in treating chronic HCV infection

Researchers at Penn Medicine, in collaboration with a multi-center international team, have shown that a protease inhibitor, simeprevir, a once a day pill, along with interferon and ribavirin has proven as effective in treating chronic Hepatitis C virus infection (HCV) as telaprevir with interferon and ribavirin, the standard of care in developing countries.

10 Dec 2014

Epizyme's PRMT5 inhibitor shows efficacy in pre-clinical models of mantle cell lymphoma

Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the results from a preclinical study showing in vitro and in vivo activity of its first-in-class PRMT5 inhibitor EPZ015666 in mantle cell lymphoma (MCL), an aggressive form of non-Hodgkin lymphoma (NHL).

10 Dec 2014

Epizyme presents EPZ-5676 Phase 1 trial results for acute leukemia at ASH 2014

Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the presentation of results from the company’s Phase 1 trial of EPZ-5676, a potent and selective inhibitor of the DOT1L histone methyltransferase (HMT).

10 Dec 2014

ContraVir begins pharmacokinetic study of FV-100 for treating shingles

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has initiated a pharmacokinetic (PK) study of FV-100, the Company's clinical-stage antiviral for treating shingles.

9 Dec 2014

Kiadis Pharma reports positive interim data from ATIR Phase II clinical study

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, today announces positive interim data from the ongoing Phase II clinical study with its lead product ATIR.

9 Dec 2014

Doctors prescribe fewer opioids for pain as prescription drug abuse rises

Nine in 10 primary care physicians say that prescription drug abuse is a moderate or big problem in their communities and nearly half say they are less likely to prescribe opioids to treat pain compared to a year ago, new Johns Hopkins Bloomberg School of Public Health research suggests.

9 Dec 2014

New way to wirelessly detect hazardous gases, environmental pollutants

MIT chemists have devised a new way to wirelessly detect hazardous gases and environmental pollutants, using a simple sensor that can be read by a smartphone.

9 Dec 2014

Cornerstone Pharmaceuticals initiates CPI-613 Phase I trial in patients with B-cell NHL

Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a Phase I clinical trial assessing the safety and efficacy of escalating doses of CPI-613, in combination with bendamustine and rituximab, in patients with relapsed or refractory B-cell Non-Hodgkin lymphoma (NHL).

8 Dec 2014

New fluorescence-imaging agent could improve diagnosis, guide surgeons during tumor removal

CEA-Leti and CLARA today announced the development of a new fluorescence-imaging agent that could significantly increase surgeons’ accuracy when removing cancerous tumors.

8 Dec 2014

New report examines how companies educate employees, prepare for new product launch

When a pharmaceutical company is gearing up for a new product launch, effective brand and communications leaders focus not only on external communications but also internal disease state communication and education directed at employees.

7 Dec 2014

Emerging strategies to boost healthy RBCs may reduce burden of anemia linked to blood disorders

Emerging treatment approaches may reduce the burden of anemia associated with blood disorders by enhancing production of healthy red blood cells, according to data presented today at the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Drugs we release into the environment significantly affect plant growth, study reveals

The drugs we release into the environment are likely to have a significant impact on plant growth, a new study has revealed.

6 Dec 2014

Promising anti-malarial compound uses novel mechanism to kill malaria parasite

An international research collaborative has determined that a promising anti-malarial compound tricks the immune system to rapidly destroy red blood cells infected with the malaria parasite but leave healthy cells unharmed. St. Jude Children's Research Hospital scientists led the study, which appears in the current online early edition of the Proceedings of the National Academy of Sciences.

5 Dec 2014

Janssen, American Diabetes Association team up to launch national educational campaign on diabetes

Janssen Pharmaceuticals, Inc. today announced a collaboration with the American Diabetes Association to launch Teaming Up to Take On Diabetes, a national educational campaign intended to help the nearly 30 million Americans living with diabetes better understand and manage the disease.

5 Dec 2014

Isis Pharmaceuticals CEO honored with SCRIP Lifetime Achievement Award

Stanley T. Crooke, Ph.D., M.D., founder, CEO and chairman of the board of directors of Isis Pharmaceuticals, Inc., has been awarded the 2014 SCRIP Lifetime Achievement Award, one of the most prestigious of its kind in the pharmaceutical and biotechnology industries worldwide.

5 Dec 2014

Added benefit of nalmefene not proven for alcohol dependence

Nalmefene (trade name Selincro) has been approved since February 2013 for people with alcohol dependence who currently drink a lot of alcohol, but who do not have physical withdrawal symptoms and who do not require immediate detoxification. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether the drug offers an added benefit over the appropriate comparator therapy in this patient group.

5 Dec 2014

Phase IIb trial shows platinum-resistant ovarian patients treated with PM1183 live longer

Zeltia announces today that its pharmaceutical division PharmaMar has data from a group of 33 randomized patients with platinum-resistant ovarian cancer demonstrating that PM1183 shows a significantly superior median overall survival compared to topotecan.

4 Dec 2014

CorMedix seeks QIDP designation from FDA for Neutrolin Catheter Lock Solution

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease, has filed a request with the U.S. Food and Drug Administration for designation of its lead product candidate, Neutrolin Catheter Lock Solution, as a qualified infectious disease product (QIDP) pursuant to the Generating Antibiotic Incentives Now (GAIN) title of the Food and Drug Administration Safety and Innovation Act.

4 Dec 2014

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration for its New Drug Applications (NDAs) for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in pediatric patients.

4 Dec 2014

Pharmaceuticals News and Research

Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Study: Simeprevir-based therapy proves effective in treating chronic HCV infection

Epizyme's PRMT5 inhibitor shows efficacy in pre-clinical models of mantle cell lymphoma

Epizyme presents EPZ-5676 Phase 1 trial results for acute leukemia at ASH 2014

ContraVir begins pharmacokinetic study of FV-100 for treating shingles

Kiadis Pharma reports positive interim data from ATIR Phase II clinical study

Doctors prescribe fewer opioids for pain as prescription drug abuse rises

New way to wirelessly detect hazardous gases, environmental pollutants

Cornerstone Pharmaceuticals initiates CPI-613 Phase I trial in patients with B-cell NHL

New fluorescence-imaging agent could improve diagnosis, guide surgeons during tumor removal

New report examines how companies educate employees, prepare for new product launch

Emerging strategies to boost healthy RBCs may reduce burden of anemia linked to blood disorders

Drugs we release into the environment significantly affect plant growth, study reveals

Promising anti-malarial compound uses novel mechanism to kill malaria parasite

Janssen, American Diabetes Association team up to launch national educational campaign on diabetes

Isis Pharmaceuticals CEO honored with SCRIP Lifetime Achievement Award

Added benefit of nalmefene not proven for alcohol dependence

Phase IIb trial shows platinum-resistant ovarian patients treated with PM1183 live longer

CorMedix seeks QIDP designation from FDA for Neutrolin Catheter Lock Solution

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence